• Lantheus Holdings, Inc. reported first-quarter 2026 results with revenue rising to US$377.33 million and net income reaching US$118.42 million, alongside FDA approval for PYLARIFY TruVu and tentative approval for PNT2003 in its radiopharmaceutical portfolio.
• The combination of higher earnings, gains from the SPECT business sale, and progression of multiple late-stage imaging and therapeutic assets underscores Lantheus’s push to reshape its mix toward PET-based oncology and neuroendocrine products.
• Next, we’ll examine how the PYLARIFY TruVu approval and broader pipeline progress may reshape Lantheus’s investment narrative and future expectations.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Lantheus Holdings Investment Narrative Recap

To own Lantheus, you need to believe it can gradually reduce its reliance on PYLARIFY while building a broader PET-based oncology and neuroendocrine franchise. The latest quarter supports that shift, with earnings helped by the SPECT divestiture and new FDA decisions, but also highlights that modest top line growth and pricing pressure keep short term revenue execution and PSMA competition as the central risk. Overall, this news reinforces the core thesis rather than materially changing it.

Among the recent announcements, the FDA approval of PYLARIFY TruVu looks most relevant, because it directly targets one of the key near term catalysts: improving the economics and reach of the PSMA PET business. By enabling larger batch sizes and more efficient manufacturing, TruVu could help Lantheus defend its PSMA position and support margins, which matters as the company works to offset softer PYLARIFY trends with upcoming launches like MK-6240, OCTEVY, and PNT2003.

But while TruVu may support the PSMA franchise, investors should also be aware that pricing and reimbursement pressure in this market could still...

Lantheus Holdings' narrative projects $1.9 billion revenue and $478.1 million earnings by 2029. This requires 7.1% yearly revenue growth and a $244.5 million earnings increase from $233.6 million today.

Uncover how Lantheus Holdings' forecasts yield a $93.92 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts took a much more cautious view, assuming revenue growth of only about 3.7 percent a year and earnings of roughly US$286.6 million by 2029, even before this quarter’s approvals and TruVu catalyst. Their narrative leans heavily on ongoing PSMA pricing pressure and slower pipeline uptake, so the fresh data from Q1 2026 could either soften or reinforce that skepticism over time.

Explore 6 other fair value estimates on Lantheus Holdings - why the stock might be worth 16% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.